Johnson & Johnson

Innovative

Medicine &

MedTech

Portfolio

EXECUTIVE HEALTHCARE STRATEGY &

INNOVATION CASE STUDY

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 2

Executive Overview

Advancing the health of humanity through a focused, science-led

strategy.

Following the successful separation of its Consumer Health business

(Kenvue) in 2023, Johnson & Johnson has emerged as a streamlined, high-

growth entity. The organization is now centered on two symbiotic pillars:

Innovative Medicine

and

MedTech

Strategic Realignment

This transformation is not merely organizational; it is a strategic pivot

toward areas of highest medical value. By concentrating resources on

breakthrough biopharmaceuticals and advanced medical technology, J&J

is positioning itself to lead the next era of precision medicine.

The Two-Pillar Synergy

The convergence of medicine and technology allows J&J to treat, cure,

and prevent diseases more effectively. While Innovative Medicine

addresses the biological roots of disease, MedTech provides the

intervention and monitoring tools necessary for comprehensive

patient care.

$15B+

ANNUAL R&D SPEND

100+

PIPELINE ASSETS

25+

BLOCKBUSTER DRUGS

Innovative Medicine

Pioneering breakthrough therapies across six core therapeutic

areas.

Oncology Leadership

J&J is a global leader in hematology

and is rapidly expanding its

footprint in solid tumors. The focus

is on curative pathways, utilizing

cell therapies (CAR-T) and bispecific

antibodies to target previously

untreatable cancers.

Flagship Assets:

DARZALEX,

CARVYKTI, and TECVAYLI continue

to redefine standards of care in

multiple myeloma.

Immunology &

Neuroscience

Maintaining a multi-decade

leadership in immunology, J&J is

transitioning toward next-

generation IL-23 inhibitors. In

Neuroscience, the focus remains on

mood disorders and

neurodegenerative diseases with

significant unmet needs.

Key Therapies:

TREMFYA,

STELARA, and SPRAVATO.

Therapeutic Portfolio Mapping

Relative Distribution of Pipeline Assets by Phase (Internal Projection)

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 4

Targeted Excellence

The Oncology Ecosystem

J&J’s oncology strategy focuses on four pillars: Hematologic Malignancies,

Prostate Cancer, Lung Cancer, and Bladder Cancer. By integrating

diagnostics with therapeutics, the company ensures the right treatment for

the right patient at the right time.

Cell Therapy & Bispecifics:

The success of Carvykti (BCMA-directed

CAR-T) demonstrates J&J's ability to scale complex manufacturing for

personalized medicine.

Immunology Frontiers

The immunology portfolio is evolving to address the underlying drivers of

chronic inflammation. J&J's research into the IL-23 pathway has produced

industry-leading results in psoriasis and inflammatory bowel disease (IBD).

Indication Expansion:

Systematic clinical trial

programs to expand existing

labels (e.g., Tremfya for Crohn’s

Disease).

Lifecycle Management:

Strategic focus on

transitioning patients to next-

generation biologics ahead of

patent cliffs.

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 5

Manufacturing &

Infrastructure

Building a resilient, digitalized global supply chain for the future of

medicine.

J&J operates one of the world's most sophisticated manufacturing

networks. The shift toward biologics and personalized cell therapies has

necessitated a massive investment in sterile manufacturing and cold-chain

logistics.

Research Infrastructure

Digital Twins:

Using AI to simulate manufacturing processes before

physical implementation.

Cell Therapy Centers:

Specialized facilities designed for the rapid

turnaround of patient-specific treatments.

Sustainability:

Targeting 100% renewable electricity for all global

operations by 2025.

Supply Chain Resilience

Utilizing predictive analytics to anticipate disruptions, ensuring that

life-saving medicines reach patients regardless of global volatility.

•

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 6

MedTech Innovation

Where precision engineering meets clinical expertise.

Surgery &

Orthopaedics

The Ethicon and DePuy Synthes

brands represent the gold standard

in surgical stapling and

orthopaedic implants. Digital

integration now allows for pre-

operative planning and intra-

operative guidance.

Interventional

Solutions

A rapidly growing segment focused

on electrophysiology and heart

failure. The Biosense Webster

business continues to lead in

mapping and ablation

technologies.

The Vision Portfolio

Comprehensive eye health solutions ranging from ACUVUE contact lenses

to advanced surgical lasers for cataract and refractive surgery.

1 in 3

SURGERIES USE J&J PRODUCTS

Top 2

MARKET POSITION IN MOST CATEGORIES

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 7

Robotics & Digital Surgery

Transforming the operating room with the Ottava and Monarch

platforms.

The Monarch Platform

The Monarch platform is a first-of-its-kind robotic system for bronchoscopy,

enabling physicians to reach small, hard-to-access nodules in the lung for

earlier diagnosis and treatment of lung cancer.

Ottava: The Next Frontier

Ottava is J&J’s soft-tissue robotic surgical system. Unlike existing bulky

systems, Ottava features six arms integrated into the operating table,

providing a smaller footprint and greater clinical flexibility.

Data-Driven Surgery

J&J is building a digital ecosystem that captures surgical video and

data to provide real-time insights to surgeons, potentially reducing

complications and improving surgical technique.

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 8

Cardiovascular Innovation

Leading the way in heart rhythm management and circulatory

support.

Cardiovascular disease remains the leading cause of death globally. J&J has

aggressively expanded its portfolio to address the most critical aspects of

heart health.

Electrophysiology:

Biosense

Webster’s mapping and

ablation systems (e.g., CARTO

3) allow for precise treatment

of atrial fibrillation.

Pulsed Field Ablation:

Pioneering non-thermal

energy sources to treat

arrhythmias with higher safety

and efficiency.

Abiomed & Shockwave Medical

The acquisitions of Abiomed (Impella heart pumps) and Shockwave

Medical (Intravascular Lithotripsy) have positioned J&J as a leader in heart

recovery and the treatment of calcified arterial disease.

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 9

Strategic Acquisitions

Inorganic growth as a catalyst for innovation.

J&J utilizes a disciplined capital allocation strategy to acquire technologies

that complement its existing strengths or provide entry into high-growth

"white space" markets.

Recent Major Transactions

Abiomed ($16.6B):

World leader in heart recovery technology.

Shockwave Medical ($13.1B):

Breakthrough in intravascular

lithotripsy for calcified arteries.

Ambrx ($2B):

Strengthening the oncology pipeline with

Antibody-Drug Conjugates (ADCs).

Strategic Integration

Success at J&J is measured not by the acquisition itself, but by the

successful integration of the technology into the global commercial and

R&D engine.

•

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 10

R&D, AI & Clinical Innovation

Harnessing data science to accelerate the pace of discovery.

J&J is embedding Artificial Intelligence across the entire value chain—from

identifying new drug targets to optimizing clinical trial recruitment.

AI in Drug Discovery

Using machine learning to screen

millions of compounds in silico,

reducing the time from target

identification to lead optimization

by years.

Precision Medicine

Utilizing biomarkers and genomic

data to identify patient subgroups

most likely to respond to specific

therapies.

The "World without Disease" Vision:

A commitment to intercepting

disease at its earliest stage through advanced diagnostics and early

intervention.

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 11

Financial Performance

Delivering sustainable value through disciplined execution.

J&J’s financial profile is defined by diversified revenue streams and a strong

balance sheet that allows for continued investment through economic

cycles.

Revenue Composition

Innovative Medicine:

~$50B+ Annual Revenue

MedTech:

~$30B+ Annual Revenue

Capital Allocation Priorities

Organic R&D Investment

Dividend Growth (60+ years of consecutive increases)

Strategic M&A

Share Repurchases

The company remains focused on delivering mid-single-digit compound

annual growth rates (CAGR) for the remainder of the decade.

•

Johnson & Johnson Innovative Medicine & MedTech Portfolio — page 12

Executive Outlook

Building the future of healthcare.

Johnson & Johnson is uniquely positioned to lead the healthcare industry

into its next chapter. By combining the profound scientific depth of

Innovative Medicine with the technical precision of MedTech, J&J is

creating a holistic healthcare ecosystem.

Key Strategic Priorities for 2026 and Beyond:

Maximize the commercial potential of the "Next Wave" oncology

pipeline.

Fully integrate the Ottava robotic system into the global surgical

market.

Expand cardiovascular leadership into heart failure and stroke

prevention.

Leverage AI to create a more agile and efficient R&D organization.

"We are at a point in human history where the convergence of biology

and technology will allow us to change the trajectory of health

forever."

•

Johnson & Johnson Innovative Medicine & MedTech Portfolio

Prompt to Clone This Johnson & Johnson Innovative Medicine & MedTech Portfolio

Apply this example's core structure, strategic pacing, and structural hierarchy directly to your own topic.

What are you generating today?